NESS-040C5 is a potent
cannabinoidagonist which was developed for the treatment of
glaucoma.[1] It has reasonable selectivity for the
CB2 receptor subtype, having a CB2 affinity of 0.4nM, and 25x selectivity over the related
CB1 receptor.[2]
^Hanus LO, Mechoulam R (2010). "Novel natural and synthetic ligands of the endocannabinoid system". Current Medicinal Chemistry. 17 (14): 1341–59.
doi:
10.2174/092986710790980096.
PMID20166928.